Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 1, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 3,950,000 Ordinary shares.
- Purchase Price: 1,264.95 pence per share.
- Treasury Shares Held: 333,449,158 shares (representing 5.56% of total voting rights).
- Shares in Issue: 5,688,049,876 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares and the increase in Treasury holdings following the August 1 transaction. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (3,950,000 shares at 1,264.95 pence) against the company's cash position in other filings.
- Confirm the updated total voting rights denominator (5,688,049,876 shares) for compliance with Disclosure and Transparency Rules.
- Check subsequent filings to determine if the repurchase program has concluded or if further buybacks are planned.